Outgoing CEO Carolyn Starrett to transition as Senior Advisor following a tenure marked by global growth and data leadership
Flatiron Health today announced the appointment of Nathan Hubbard as Chief Executive Officer (CEO). Hubbard succeeds Carolyn Starrett, who has led Flatiron since 2021 and will be transitioning to a senior advisor role after nearly a decade of transformative leadership.
“I’m honored to step into this role,” said Hubbard. “With deep roots in biopharma, life sciences, and technology, I understand the critical role Flatiron plays in accelerating cancer research and improving care. I’m committed to building on the strong foundation Carolyn and the team have created and ensuring continuity as we continue delivering meaningful impact for patients, partners, and the oncology community.”
With more than 20 years of leadership across biopharma, healthcare and data-driven businesses, Hubbard brings a unique and rare blend of strategic insight, commercial acumen, and operational excellence to his role as CEO of Flatiron Health. Prior to this appointment, he served in multiple senior leadership roles where he played a critical role in aligning commercial strategy, scaling operations, and advancing cross-functional innovation across global markets. Hubbard’s ability to lead mission-driven teams, navigate complex ecosystems, and drive sustained performance positions him strongly to guide Flatiron through its next phase of growth and impact.
Carolyn Starrett, who first joined Flatiron in 2016, leaves behind a legacy of strategic clarity and customer-centric innovation. During her tenure as CEO, Starrett led the company through a period of significant growth and transformation. She oversaw the expansion of Flatiron Horizon, the company’s real-world data platform, from 400,000 to more than 5.5 million patients and launched the company’s evidence services business to deliver faster, more flexible insights to biopharma partners. She also guided Flatiron’s global expansion, scaling its research network to more than 30 sites across the United Kingdom, Germany and Japan. Under her leadership, Flatiron’s electronic health record OncoEMR®, grew to serve over 4,500 providers across the US, and its real-world data has powered more than 1,800 publications, reshaping how cancer care and research are delivered to patients. During this time, the company nearly doubled its revenue run rate, while building a more scalable and sustainable operating model, reinforcing its position as the market leader in oncology evidence generation and its growing impact across the healthcare ecosystem.
“It’s been the honor of my career to lead Flatiron over the last four and a half years,” said Starrett. “We’ve never been in a stronger position, and I’m confident the company will move even faster toward its full potential with Nathan at the helm. Over his five year tenure at Flatiron, Nathan has built our international business and presence from the ground up, expanded and deepened our partnerships with leading biopharma companies and played a critical role in shaping our strategic vision. He brings a sharp understanding of our industry, a global perspective, and a deep commitment to our mission, making him the right leader to take Flatiron forward.”
As a long-time partner, Roche expressed confidence in the transition and in Nathan’s ability to lead Flatiron.
“Nathan’s combination of entrepreneurial drive, operational depth, and strong alignment with Flatiron’s mission makes him the right leader to carry the business forward,” said Thomas Schinecker, CEO of Roche. “Flatiron plays an increasingly critical role in advancing oncology innovation, and I’m confident that under Nathan’s leadership, the company will continue to shape the future of cancer research and care.”
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
